Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: An analysis of 1066 cases of a german HCC registry

Journal of Clinical Gastroenterology

Volumn 48, Issue 3, 2014, Pages 279-289

  Weinmann, Arndt ^a   Koch, Sandra ^a   Niederle, Ina M ^a   Schulze Bergkamen, Henning ^b   König, Jochem ^a   Hoppe Lotichius, Maria ^a   Hansen, Torsten ^a   Pitton, Michael B ^a   Düber, Christoph ^a   Otto, Gerd ^a   Schuchmann, Marcus ^a   Galle, Peter R ^a   Wörns, Marcus A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

BCLC; Epidemiology; HCC; Hepatocellular carcinoma; Liver transplantation; SIRT; Sorafenib; Survival; TACE; Therapy

Indexed keywords

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894044915     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182a8a793     Document Type: Article

References (51)

1. Politi F, Amico GD, Pagliaro L. A worldwide problem and the major risk factors. Dig Dis. 1991;36:962-972.
2. Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 2004;127: S5-S16.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-2576.
4. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118-1127.
5. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004;127(SUPPL1): S87-S96.
6. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database. Hepatology. 2011;54:463-471.
7. Starley BQ, Calcagno CJ, Harrison Sa. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology. 2010;51:1820-1832.
8. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384.
9. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology. 2005;42:44-52.
10. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
11. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348: 1625-1638.
12. Lesurtel M, Centers T, Clavien P. 2010 International Consensus Conference on Liver Transplantation for Hepatocellular Carcinoma: Texts of experts. Liver Transpl. 2011;17(SUPPL2):s1-s5.
13. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 1999;19:329-338.
14. Bruix J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol. 2001;35:421-430.
15. Vauthey J-N, Ribero D, Abdalla EK, et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: Validation of a uniform staging after surgical treatment. J Am Coll Surg. 2007;204:1016-1027; discussion 1027-8.
16. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: In vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17(pt 1):335-342.
17. Pöpperl G, Helmberger T, Münzing W, et al. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm. 2005;20: 200-208.
18. Strumberg D, Richly H, Hilger Ra, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-972.
19. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet. 2002;359:1734-1739.
20. Lo C, Ngan H, Tso W, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
21. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429-442.
22. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(SUPPL1):S179-S188.
23. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liv Transpl. 2006;12:1260-1267.
24. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25.
25. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.
26. Salem R. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: A comprehensive report of long-Term outcomes. Gastroenterology. 2010;138:52-64.
27. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: How hopeful should we be? Oncologist. 2007; 11:790-800.
28. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
29. Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
30. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020-1022.
31. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
32. Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. XV, p. 649 with CD-ROM. New York: Springer New York; 2010.
33. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918-928.
34. Talian LII, Clip PR. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000;31: 840-845.
35. Kirchner G, Kirovski G, Hebestreit A, et al. Epidemiology and survival of patients with hepatocellular carcinoma in Southern Germany. Int J Clin Exp Med. 2010;3:169-179.
36. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: A retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-1868.
37. Erhardt A, Zhu E, Blondin D, et al. Increasing number and improved survival of patients with hepatocellular carcinoma from 1988 to 2007: Data of a German University Clinic. Z Gastroenterol. 2011;49:720-727.
38. Greten TF, Wedemeyer H, Manns MP, et al. The prevention of virally mediated carcinogenesis. Dtsch Arztebl. 2006;103: A1817-1823.
39. Von Hahn T, Ciesek S, Wegener G, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol. 2011;46:1092-1098.
40. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2011;56:1-9.
41. Hucke F, Sieghart W, Schöniger-Hekele M, et al. Clinical characteristics of patients with hepatocellular carcinoma in Austria-is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551.
42. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37(SUPPL2):S88-S94.
43. Santi V, Buccione D, Micoli A Di, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397-405.
44. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis. 2009;27:80-92.
45. Alacacioglu A, Somali I, Simsek I, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: Outcome of multicenter study. Jpn J Clin Oncol. 2008;38:683-688.
46. Roberts SK, Kemp W. Hepatocellular carcinoma in an Australian tertiary referral hospital 1975-2002: Change in epidemiology and clinical presentation. J Gastroenterol Hepatol. 2007;22:191-196.
47. Global status report on alcohol and health. Geneva; 2011. Available at http://www.who.int/substance-Abuse/publica tions/global-Alcohol-report/en/World Health Organisation (WHO). Accessed August 28, 2013.
48. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359. e2.
49. Davila Ja, Morgan RO, Richardson Pa, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010;52:132-141.
50. D'Avola D, Iñarrairaegui M, Pardo F, et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol. 2011;18:1964-1971.
51. Peck-Radosavljevic M. Hepatocellular carcinoma: The place of new medical therapies. Ther Adv Gastroenterol. 2010;3: 259-267.